"It’s an exciting time for cancer care in our region. Together, the Tri-Cities Cancer Center (TCCC) and Kadlec are charting a path forward to ensure continuity and growth of well-integrated cancer care services for our region. Through this integration, we will be enhancing cancer care in our region offering a full continuum of care that includes hematology, medical oncology, radiation oncology, surgical specialties, research, genetics, palliative care, survivorship and support programs."

During the past decade, Tri-Cities Cancer Center conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tri-Cities Cancer Center" #1 sponsor was "Alliance for Clinical Trials in Oncology" with 3 trials, followed by "National Cancer Institute (NCI)" with 3 trials sponsored, "Radiation Therapy Oncology Group" with 2 trials sponsored, "GOG Foundation" with 1 trials sponsored and "NSABP Foundation Inc" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tri-Cities Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 8 trials as a collaborator, "NRG Oncology" with 5 trials as a collaborator, "Canadian Cancer Trials Group" with 3 trials as a collaborator, "European Organisation for Research and Treatment Center (EORTC)" with 1 trials as a collaborator and "Radiation Therapy Oncology Group" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Tri-Cities Cancer Center" are "Breast Cancer" (2 trials), "Stage II Breast Cancer" (2 trials), "Brain and Central Nervous System Tumors" (1 trials), "Breast Ductal Carcinoma In Situ" (1 trials) and "Cervical Adenocarcinoma" (1 trials). Many other conditions were trialed in "Tri-Cities Cancer Center" in a lesser frequency.

Most popular intervention types in "Tri-Cities Cancer Center" are "Radiation" (9 trials), "Drug" (5 trials), "Other" (5 trials), "Biological" (4 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Intensity-Modulated Radiation Therapy" (3 trials), "Laboratory Biomarker Analysis" (3 trials), "Cisplatin" (2 trials), "Quality-of-Life Assessment" (2 trials) and "5 FUCMT (chemoradiation)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Tri-Cities Cancer Center" are 7 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Tri-Cities Cancer Center". undefined are not yet recruiting, 2 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Tri-Cities Cancer Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Tri-Cities Cancer Center, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".